Clinical & Translational Oncology最新文献

{"title":"Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).","authors":"Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma","doi":"10.1007/s12094-025-03865-6","DOIUrl":"https://doi.org/10.1007/s12094-025-03865-6","url":null,"abstract":"<p><p>Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency and predictors of caregiver burden among patients with cancer receiving palliative cancer treatment.","authors":"Juan Luis Torres-Tenor, Elsa Bernal-Hertfelder, Ana Pertejo-Fernández, Jorge Luis Ramón-Patiño, Andrés Redondo, Alberto Alonso-Babarro, Eduardo Bruera","doi":"10.1007/s12094-025-03885-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03885-2","url":null,"abstract":"<p><strong>Purpose: </strong>Assess the frequency of caregiver burden among patients with advanced cancer receiving palliative anticancer treatment. Compare characteristics of those who show caregiver burden versus those who do not.</p><p><strong>Methods/patients: </strong>This is a cross-sectional study in two university hospital oncology departments. Caregivers completed the Reduced Zarit Burden Interview and Emotional Distress Thermometer. Data were analyzed to identify factors associated with caregiver burden.</p><p><strong>Results: </strong>79 informal primary caregivers participated, mostly women (65%, N = 51), middle-aged (median 57, SD = 9), employed (54%), and spouses (58%, N = 46). Most had medium economic status (70%, N = 55), no other dependents (51%, N = 40), support from other caregivers (56%, N = 44), and good self-rated health (82%, N = 65). Caregiver burden affected 61% (N = 48), more often women (p = 0.049), those with high stress (p = 0.001), and when more people were involved in patient care (p = 0.048).</p><p><strong>Conclusions: </strong>Caregiver burden is common in informal primary caregivers of patients with advanced cancer receiving palliative treatment, especially in highly stressed women.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability of core needle biopsy for HER2-low early-stage breast cancer.","authors":"C M Ciniselli, P Verderio, V Duroni, P Baili, S Pizzamiglio, F G de Braud, S Folli, C Depretto, G Scaperrotta, M C De Santis, M G Carnevale, C De Marco, A Vingiani, G Pruneri, S Di Cosimo","doi":"10.1007/s12094-025-03877-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03877-2","url":null,"abstract":"<p><strong>Background: </strong>The reliability of core needle biopsy (CNB) for HER2-positive breast cancer is well established. However, data on HER2-low and the potential for inconsistencies with surgical samples are limited.</p><p><strong>Materials and methods: </strong>Concordance between CNB and surgical samples was assessed using the unweighted Cohen kappa statistic (Kc) in a consecutive series of 776 treatment-naïve early-stage breast cancer patients. Logistic regression models were used to evaluate the association between concordance and clinico-pathological features.</p><p><strong>Results: </strong>The agreement for HER2-positive status between CNB and surgical specimens was high at 95%, with a Kc value of 0.86 indicating almost perfect agreement. However, 65 of 123 (53%) cases initially classified as HER2-0 were reclassified as HER2 1 + or 2 + /ISH-negative, and 89 of 374 (24%) cases initially classified as HER2 1 + /2 + were HER2-0 in surgical samples. This resulted in a Kc value of 0.22, indicating fair agreement in classifying HER2-0 versus HER2-low breast cancer. Tumor size was a significant factor influencing discordance, with tumors larger than 2 cm having double the risk of misclassification.</p><p><strong>Conclusion: </strong>These findings suggest that HER2 status should be retested, particularly for large tumors initially diagnosed as HER2-0, in light of new effective therapies for HER2-low breast cancer, such as antibody-drug conjugates.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.","authors":"Wei Yang, Junqi Long, Gege Li, Jiashuai Xu, Yining Chen, Shijie Zhou, Zhidong Liu, Shuangtao Zhao","doi":"10.1007/s12094-025-03861-w","DOIUrl":"https://doi.org/10.1007/s12094-025-03861-w","url":null,"abstract":"<p><strong>Background: </strong>In lung adenocarcinoma (LUAD), there remains a dearth of efficacious diagnostic studies including some inflammation-related genes to identify the LUAD subgroups with different clinical outcomes.</p><p><strong>Methods: </strong>First, two molecular subgroups were identified with mRNA expression profiling from The Cancer Genome Atlas (TCGA) by K-means algorithm. Gene set enrichment analysis (GSEA), immune infiltration, and Gene set variation analysis (GSVA) were applied to explore the biological functions between these two subtypes. Then, univariate and multivariate Cox regression analyses were selected to evaluate the independence of these subtypes in LUAD. Next, lasso regression was applied to identify the high-precision mRNAs to predict the subtype with favorable prognosis. Finally, a two-mRNA model was constructed using the method of multivariate Cox regression, and the effectiveness of the model was validated in a training set (n = 310) and three independent validation sets (n = 1.</p><p><strong>Results: </strong>Comprehensive genomic analysis was conducted of 310 LUAD samples and identified two subtypes associated with molecular classification and clinical prognosis: immune-enriched and non-immune-enriched subgroup. Then, a new model was developed based on two mRNAs (MS4A1 and MS4A2) in TCGA dataset and divided these LUAD patients into high-risk and low-risk subgroup with significantly different prognosis (HR = 1.644 (95% CI 1.153-2.342); p < 0.01), which was independence of the other clinical factors (p < 0.05). In addition, this new model had similar predictive effects in another three independent validation sets (HR > 1.445, p < 0.01).</p><p><strong>Conclusions: </strong>We constructed a robust model for predicting the risk of LUAD patients and evaluated the clinical outcomes independently with strong predictive power. This model stands as a reliable guide for implementing personalized treatment strategy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask.","authors":"Daniela Alterio, Michał Gola, Mattia Zaffaroni, Maria Giulia Vincini, Carlo Guglielmo Cattaneo, Cynthia Aristei, Gabriella Macchia, Vitaliana De Sanctis, Francesca DeFelice","doi":"10.1007/s12094-025-03868-3","DOIUrl":"https://doi.org/10.1007/s12094-025-03868-3","url":null,"abstract":"<p><strong>Background: </strong>Human papilloma virus (HPV)-related cancers are well-known clinical entities in different body sites. Cervix, anus, and oropharynx are the most common tumors related to the virus infection. The aim of this work was to highlight similarities and differences among HPV-related cancers of different subsites.</p><p><strong>Methods: </strong>The narrative review was focused on the following topics: (1) epidemiology, (2) prognostic factors, (3) treatment approaches, (4) radiomic analysis, (5) radiosensitivity, (6) de-escalation strategies. Common aspects as well as differences have been highlighted for cervical, anal and oropharyngeal HPV-related tumors.</p><p><strong>Results: </strong>Common prognosticators in terms of patients characteristics (anemia, smoking habits), tumor histology (lymph node extracapsular extension) biological features (high circuating HPV DNA), blood cell immunomodulating response (high level of tumor-infiltrating lymphocytes and high neutrophil-to-lymphocyte ratio) as good parameters of radiosensitivity (radiosensitivity index RSI, and genomic adjusted radiation dose GARD) have been found among the analyzed tumor subsites. On the contrary, other aspects like treatment approaches (different RT techniques and doses), radiomic analysis and de-intensification strategies were found to be different among tumors.</p><p><strong>Conclusion: </strong>HPV-related tumors have several common prognostic and predictive features that do not translate into common therapeutic approaches and de-intensification strategies. A better understanding of which factors are associated with a high risk of early recurrence or favourble clinical outcomes could help in guiding clinical assessment and screening activities and might improve efforts for precision medicine.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer.","authors":"Junwei Yin, Yongli Zhao, Junping Yin, Shanshan Yang","doi":"10.1007/s12094-025-03879-0","DOIUrl":"https://doi.org/10.1007/s12094-025-03879-0","url":null,"abstract":"<p><strong>Background: </strong>Liver metastases from colorectal cancer are a common and serious complication that significantly impacts patient survival. The aim of this study is to investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of liver metastases from colorectal cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 120 patients with liver metastases from colorectal cancer who were treated in our hospital from January 2018 to January 2023. The patients were divided into two groups based on the treatment they received: the TACE group (n = 60) and the TACE combined with RFA group (n = 60). The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups, and treatment-related adverse effects were recorded.</p><p><strong>Results: </strong>The TACE combined with RFA group showed significantly better OS (22 months vs. 18 months) and PFS (13 months vs. 10 months) compared to the TACE alone group (P < 0.05). The ORR in the TACE combined with RFA group was 61.7%, significantly higher than 40% in the TACE alone group (P < 0.05). The DCR showed no significant difference between the two groups, with 86.7% (52/60) in the TACE combined with RFA group and 78.3% (47/60) in the TACE alone group (P > 0.05). There were no significant differences in treatment-related adverse effects between the two groups (P > 0.05).</p><p><strong>Conclusion: </strong>These findings suggest that TACE combined with RFA may offer a potential option for improving OS, PFS, and ORR in patients with liver metastases from colorectal cancer, without increasing significant adverse effects, setting a new potential standard of care in the treatment of this disease.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budget impact analysis of neoadjuvant nivolumab for non-small cell lung cancer in the Chilean public healthcare system: An exploratory economic assessment.","authors":"Daniela Paredes-Fernández, Rony Lenz-Alcayaga, Francisco Orlandi-Jorquera","doi":"10.1007/s12094-025-03872-7","DOIUrl":"https://doi.org/10.1007/s12094-025-03872-7","url":null,"abstract":"<p><strong>Purpose: </strong>Effective and sustainable treatments to improve patient outcomes are urgently needed for non-small cell lung carcinoma (NSCLC). Neoadjuvant therapies, particularly nivolumab, have shown superior outcomes in event-free survival and pathological response, yet financial coverage is scarce. We aim to provide an exploratory economic analysis to assess the implications of its incorporation into routine clinical practice.</p><p><strong>Methods: </strong>We conducted a six-step BIA (budget impact analysis) based on a decision tree model for pathways, probabilities, and resource utilization from the national payer perspective at an event-free survival (EFS) horizon. We estimated the direct cost of drugs and all healthcare-related services for two scenarios: a baseline scenario [neoadjuvant chemotherapy (CT)] and an alternative scenario [neoadjuvant nivolumab combined with chemotherapy (N + CT)].</p><p><strong>Results: </strong>The funnel-down technique determined 359 eligible patients nationwide per year. The total cost of treatment in the baseline scenario amounts to CLP $ 7315 million Chilean pesos (€ 8,063,219) per cohort, with three top cost drivers: 1L drugs after recurrence (51.98%), resection (29.33%) and 2L nivolumab (5.85%). The alternative scenario amounted to CLP $ 6853 million (€ 7,553,572), with the highest relative expenditure attributed to the N + CT scheme (61.76%), resection (31.31%), and follow-up (2.73%). Adjuvant costs decrease to 1.03%, as does the expenditure on 1L (51.98% versus 0.34%) and 2L treatments (5.85% versus 0.18%). Early intervention in NSCLC reduces the budgetary impact by 6.3% (savings of - $ 462 million (€ 509,647) per treated cohort).</p><p><strong>Conclusions: </strong>Early incorporation of N + CT optimizes healthcare expenditure by providing access to therapies that improve survival rates while reducing the need for costly treatments in advanced stages. This approach represents a dominant strategy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting MELK in tumor cells and tumor microenvironment: from function and mechanism to therapeutic application.","authors":"Pengfei Su, Qiliang Lu, Yuanyu Wang, Yiping Mou, Weiwei Jin","doi":"10.1007/s12094-024-03664-5","DOIUrl":"10.1007/s12094-024-03664-5","url":null,"abstract":"<p><p>Maternal embryonic leucine zipper kinase (MELK), a member of the adenosine monophosphate-activated protein kinase (AMPK) protein family, has been reported to be involved in the regulation of many cellular events. The aberrant expression of MELK is associated with tumorigenesis and malignant progression of various tumors. Moreover, MELK plays an essential role in the regulation of tumor microenvironment (TME), which affects the function of immune cells and the responsiveness to immunotherapy. Currently, small molecule inhibitors targeting MELK have been developed and evaluated in clinical trials. A comprehensive understanding of MELK may provide clues and confidence for subsequent basic research and scientific transformation. In this review, we provide a comprehensive overview of the structural features, molecular biological functions, and critical roles of MELK in tumors and TME, as well as the targeted agents under development for the treatment of tumors and discuss the perspective for MELK-targeted therapies for tumors.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"887-900"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SLAM family-mediated crosstalk between tumor and immune cells in the tumor microenvironment: a promising biomarker and a potential therapeutic target for immune checkpoint therapies.","authors":"Louis Boafo Kwantwi","doi":"10.1007/s12094-024-03675-2","DOIUrl":"10.1007/s12094-024-03675-2","url":null,"abstract":"<p><p>Immune cells infiltrating the tumor microenvironment are physiologically important in controlling cancers. However, emerging studies have shown that cancer cells can evade immune surveillance and establish a balance in which these immune cells support tumor progression and therapeutic resistance. The signaling lymphocytic activation molecule family members have been recognized as mediators of tumor microenvironment interactions, and a promising therapeutic target for cancer immunotherapy. This review is focused on the role of SLAM family in tumor and immune cell interactions and discusses how such crosstalk affects tumor behavior. This will shed insight into the next step toward improving cancer immunotherapy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"901-908"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group-GEIS).","authors":"Cristina Mata Fernández, Ana Sebio, Javier Orcajo Rincón, Javier Martín Broto, Antonio Martín Benlloch, David Marcilla Plaza, Antonio López Pousa, Isidro Gracia Alegría, Martina Giuppi, Erica Collado Ballesteros, Daniel Bernabeu, Enrique de Alava, Claudia Valverde Morales","doi":"10.1007/s12094-024-03602-5","DOIUrl":"10.1007/s12094-024-03602-5","url":null,"abstract":"<p><p>Ewing sarcoma is a small round-cell sarcoma characterized by gene fusion involving EWSR1 (or another TET family protein like FUS) and an ETS family transcription factor. The estimated incidence of this rare bone tumor, which occurs most frequently in adolescents and young adults, is 0.3 per 100,000/year. Although only 25% of patients with Ewing sarcoma are diagnosed with metastatic disease, historical series show that this is a systemic disease. Patient management requires multimodal therapies-including intensive chemotherapy-in addition to local treatments (surgery and/or radiotherapy). In the recurrent/refractory disease setting, different approaches involving systemic treatments and local therapies are also recommended as well as patient inclusion in clinical trials whenever possible. Because of the complexity of Ewing sarcoma diagnosis and treatment, it should be carried out in specialized centers and treatment plans should be designed upfront by a multidisciplinary tumor board. These guidelines provide recommendations for diagnosis, staging, and multimodal treatment of Ewing sarcoma.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"824-836"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}